Results 221 to 230 of about 173,364 (256)
Some of the next articles are maybe not open access.
Pulmonary arterial hypertension
La Presse Médicale, 2023Pulmonary arterial hypertension (PAH) is a rare and progressive disease characterised by remodelling of the pulmonary arteries and progressive narrowing of the pulmonary vasculature. This leads to a progressive increase in pulmonary vascular resistance and pulmonary arterial pressure and, if left untreated, to right ventricular failure and death.
Athénaïs Boucly +7 more
openaire +2 more sources
Pulmonary Arterial Hypertension
Critical Care Nursing Clinics of North America, 2011PAH is a chronic disease requiring lifelong therapy, regardless of chosen treatment options. Nurses and other providers must allow for open, honest discussion on the risks and benefits of each therapy. Determining the best treatment option for patients requires consideration of the patient's overall function and social support.
Vallerie V, McLaughlin +2 more
openaire +4 more sources
Pulmonary Arterial Hypertension
Heart Failure Clinics, 2018This article provides an overview of pulmonary arterial hypertension (PAH), beginning with the initial pathologic recognition of pulmonary hypertension more than 100 years ago and progressing to the current diagnostic categorization of PAH. It reviews the epidemiology, pathophysiology, genetics, and modern treatment of PAH.
Mark W, Dodson +2 more
openaire +2 more sources
Pulmonary Arterial Hypertension
Current Vascular Pharmacology, 2010The last 10 years have seen significant advances in the understanding of the pathophysiology and treatment of pulmonary arterial hypertension (PAH). This has included new insights into the genetics, cell-signalling pathways and pathological changes seen in the small pulmonary arteries as well as the introduction of new treatments which have improved ...
Christiana, Burt +2 more
openaire +2 more sources
Management of Pulmonary Arterial Hypertension
Seminars in Respiratory and Critical Care Medicine, 2023AbstractPulmonary arterial hypertension (PAH) is a rare pulmonary vascular disease characterized by progressive pulmonary arterial remodeling, increased pulmonary vascular resistance, right ventricular dysfunction, and reduced survival. Effective therapies have been developed that target three pathobiologic pathways in PAH: nitric oxide, endothelin-1 ...
Jason, Weatherald +3 more
openaire +2 more sources
Pulmonary arterial hypertension in women
Revue des Maladies Respiratoires, 2010Pulmonary arterial hypertension (PAH) is a rare condition characterized by sustained elevation in pulmonary arterial resistance leading to right heart failure.PAH afflicts predominantly women. Echocardiography is the initial investigation of choice for non-invasive detection of PAH but right-heart catheterization is necessary to confirm the diagnosis ...
O, Sanchez +5 more
openaire +3 more sources
Echocardiography in Pulmonary Arterial Hypertension
Current Cardiology Reports, 2019Pulmonary arterial hypertension (PAH) is a devastating disease which can result in right heart (RH) failure and death. Herein, we discuss the current clinical applications of echocardiography in PAH.Advanced echocardiographic techniques (strain, strain rate, 2D-speckle tracking strain, and three-dimensional echocardiography) may reveal in the near ...
Ferrara F. +9 more
openaire +5 more sources
Epoprostenol in pulmonary arterial hypertension
Expert Opinion on Drug Metabolism & Toxicology, 2008Pulmonary arterial hypertension (PAH) is a devastating disease leading to right heart failure and death in a relatively young patient population. In recent years novel PAH specific therapies have become available.To determine the place of epoprostenol in current PAH treatment strategies.An extensive Medline search was performed to evaluate the use of ...
Jacobs, W., Vonk Noordegraaf, A.
openaire +3 more sources
Sildenafil for Pulmonary Arterial Hypertension
American Journal of Therapeutics, 2019Pulmonary hypertension is a life-threatening illness with debilitating physical and emotional consequences. The progression of this devastating disease is characterized by a continuous increase in pulmonary vascular resistance, which results in elevated pulmonary artery pressure and leads to right heart failure.
Bhogal, Sukhdeep +5 more
openaire +3 more sources
Ambrisentan for Pulmonary Arterial Hypertension
Future Cardiology, 2005Endothelin receptor antagonists (ERAs) are an important class of agents used for the treatment of pulmonary arterial hypertension (PAH). Ambrisentan is an oral, once-daily, endothelin type-A receptor (ETA)-selective, propanoic acid class ERA under clinical investigation for the treatment of PAH.
Lewis J, Rubin +2 more
openaire +2 more sources